Levi A. Garraway

148.4k citations

173 papers · 22.5k indexed · 10 hit papers · h-index 68

Molecular Biology top 0.1%
Oncology top 0.2%
Cancer Research top 0.1%
Pulmonary and Respiratory Medicine top 0.5%
Pathology and Forensic Medicine top 0.2%

Co-authors: Eric S. Lander Matthew Meyerson Lynda Chin Gad Getz William R. Sellers Todd R. Golub David E. Fisher Laura E. MacConaill
Topics: Cancer Genomics and Diagnostics (68 papers)Melanoma and MAPK Pathways (40 papers)Genetic factors in colorectal cancer (15 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Nature Science New England Journal of Medicine
Partner nations: United States Germany Switzerland

In The Last Decade

Levi A. Garraway

171 papers receiving 22.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery and saturation analysis of cancer genes across 21 tumour types

2014 2.1k citations Levi A. Garraway, Todd R. Golub et al. profile →
Highly Recurrent TERT Promoter Mutations in Human Melanoma

2013 1.3k citations Gregory V. Kryukov, Lynda Chin et al. profile →
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

2005 1.1k citations Levi A. Garraway, Hans R. Widlund et al. profile →
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

2016 1.1k citations Eliezer M. Van Allen, Levi A. Garraway et al. profile →
BRAF mutation predicts sensitivity to MEK inhibition

2005 1.0k citations Levi A. Garraway, Gad Getz et al. profile →
Lessons from the Cancer Genome

2013 883 citations Levi A. Garraway et al. profile →
Recurrent BRAF mutations in Langerhans cell histiocytosis

2010 742 citations Gayane Badalian‐Very, Jo‐Anne Vergilio et al. Blood profile →
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

2011 732 citations Nikhil Wagle, Michael F. Berger et al. Journal of Clinical Oncology profile →
Quantitative Proteomics of the Cancer Cell Line Encyclopedia

2020 574 citations Mahmoud Ghandi, Judit Jané‐Valbuena et al. profile →
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

2014 357 citations David J. Konieczkowski, Cory M. Johannessen et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Levi A. Garraway

Since Specialization

Citations

This map shows the geographic impact of Levi A. Garraway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Levi A. Garraway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Levi A. Garraway more than expected).

Fields of papers citing papers by Levi A. Garraway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Levi A. Garraway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Levi A. Garraway. The network helps show where Levi A. Garraway may publish in the future.

Co-authorship network of co-authors of Levi A. Garraway

This figure shows the co-authorship network connecting the top 25 collaborators of Levi A. Garraway. A scholar is included among the top collaborators of Levi A. Garraway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Levi A. Garraway. Levi A. Garraway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant Melanomas 2019 ·Cancer Discovery ·Ophélia Maertens,Ryan Kuzmickas,Haley E. Manchester,(unknown),(unknown),(unknown),Terence C. Wong,Thomas De Raedt,Christian Bowman-Colin,Elodie Hatchi,Levi A. Garraway,Keith T. Flaherty,Shailja Pathania,Stephen J. Elledge,Karen Cichowski	65
2	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma 2019 ·Clinical Cancer Research ·Ali Amin‐Mansour,Suzanne George,Stefano Sioletic,Scott L. Carter,Mara Rosenberg,Amaro Taylor‐Weiner,Chip Stewart,Aaron Chevalier,Sara Seepo,Adam Tracy,Gad Getz,Jason L. Hornick,Marisa R. Nucci,Bradley J. Quade,George D. Demetri,Chandrajit P. Raut,Levi A. Garraway,Eliezer M. Van Allen,Andrew J. Wagner	18
3	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer 2016 ·Cancer Discovery ·Xiuning Le,(unknown),Pedram Razavi,Daniel J. Treacy,Flora Luo,Mahmoud Ghandi,Pau Castel,Maurizio Scaltriti,José Baselga,Levi A. Garraway	97
4	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors 2015 ·Clinical Cancer Research ·Gregory V. Kryukov,Craig M. Bielski,Kaitlin E. Samocha,Menachem Fromer,Sara Seepo,(unknown),Benjamin M. Neale,Levi A. Garraway,Christopher J. Sweeney,Mary‐Ellen Taplin,Eliezer M. Van Allen	14
5	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors 2014 ·Cancer Research ·Eva M. Goetz,Mahmoud Ghandi,Daniel J. Treacy,Nikhil Wagle,Levi A. Garraway	80
6	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection 2014 ·Molecular Cancer Research ·Hua Li,(unknown),William E. Gooding,Levi A. Garraway,Vivian Wai Yan Lui,Noah D. Peyser,Jennifer R. Grandis	91
7	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitorsbreakdown → 2014 ·Cancer Discovery ·David J. Konieczkowski,Cory M. Johannessen,Omar O. Abudayyeh,Jong Wook Kim,Zachary A. Cooper,Adriano Piris,Dennie T. Frederick,Michal Barzily-Rokni,Ravid Straussman,Rizwan Haq,David E. Fisher,Jill P. Mesirov,William C. Hahn,Keith T. Flaherty,Jennifer A. Wargo,Pablo Tamayo,Levi A. Garraway	357
8	A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition 2013 ·Cancer Discovery ·Steven R. Whittaker,Jean‐Philippe Theurillat,Eliezer M. Van Allen,Nikhil Wagle,Jessica Hsiao,Glenn S. Cowley,Dirk Schadendorf,David E. Root,Levi A. Garraway	260
9	C-RAF Mutations Confer Resistance to RAF Inhibitors 2013 ·Cancer Research ·(unknown),W. Marston Linehan,Allison M. Sawyer,Levi A. Garraway	28
10	High Throughput Mass Spectrometry-Based Mutation Profiling of Primary Uveal Melanoma 2012 ·Investigative Ophthalmology & Visual Science ·Anthony B. Daniels,Jooeun Lee,Laura E. MacConaill,Emanuele Palescandolo,Paul Van Hummelen,Scott M. Adams,Margaret M. DeAngelis,William C. Hahn,Evangelos S. Gragoudas,J. William Harbour,Levi A. Garraway,Ivana K. Kim	37
11	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profilingbreakdown → 2011 ·Journal of Clinical Oncology ·Nikhil Wagle,(unknown),Michael F. Berger,Matthew J. Davis,Allison M. Sawyer,Panisa Pochanard,Sarah M. Kehoe,Cory M. Johannessen,Laura E. MacConaill,William C. Hahn,Matthew Meyerson,Levi A. Garraway	732
12	High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing 2011 ·Cancer Discovery ·Nikhil Wagle,Michael F. Berger,Matthew J. Davis,Brendan Blumenstiel,Matthew DeFelice,Panisa Pochanard,Matthew D. Ducar,Paul Van Hummelen,Laura E. MacConaill,William C. Hahn,Matthew Meyerson,Stacey Gabriel,Levi A. Garraway	384
13	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors 2011 ·Journal of Clinical Oncology ·Patrick A. Oberholzer,Damien Kee,Piotr Dziunycz,Antje Sucker,Nyam Kamsu-Kom,Robert T. Jones,Christine Roden,(unknown),Kristin Ardlie,Emanuele Palescandolo,Adriano Piris,Laura E. MacConaill,Caroline Robert,Günther F.L. Hofbauer,Grant A. McArthur,Dirk Schadendorf,Levi A. Garraway	298
14	Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set 2010 ·Molecular Cancer Therapeutics ·Eun Sung Park,Rosalia Rabinovsky,Mark Carey,Bryan T. Hennessy,Roshan Agarwal,Wenbin Liu,Zhenlin Ju,Wanleng Deng,Yiling Lu,Hyun Goo Woo,Sang-Bae Kim,Jae‐Ho Cheong,Levi A. Garraway,John N. Weinstein,Gordon B. Mills,Ju‐Seog Lee,Michael A. Davies	71
15	An Oncogenic Role for ETV1 in Melanoma 2010 ·Cancer Research ·Judit Jané‐Valbuena,Hans R. Widlund,Sven Perner,Laura A. Johnson,(unknown),William M. Lin,Alissa C. Baker,Rosalynn M. Nazarian,Krishna G. Vijayendran,William R. Sellers,William C. Hahn,Lyn M. Duncan,Mark A. Rubin,David E. Fisher,Levi A. Garraway	81
16	Recurrent BRAF mutations in Langerhans cell histiocytosisbreakdown → 2010 ·Blood ·Gayane Badalian‐Very,Jo‐Anne Vergilio,Barbara Degar,Laura E. MacConaill,Barbara Brandner,Monica L. Calicchio,Frank C. Kuo,Azra H. Ligon,Kristen E. Stevenson,Sarah M. Kehoe,Levi A. Garraway,William C. Hahn,Matthew Meyerson,Mark D. Fleming,Barrett J. Rollins	742
17	Oncogenic Activating Mutations Are Associated with Local Copy Gain 2009 ·Molecular Cancer Research ·Barmak Modrek,Lin Ge,Ajay Pandita,Eva Lin,Sankar Mohan,Peng Yue,Steve Guerrero,William M. Lin,Thinh Q. Pham,Zora Modrušan,Somasekar Seshagiri,Howard M. Stern,Paul Waring,Levi A. Garraway,John Chant,David Stokoe,Guy Cavet	51
18	Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma 2008 ·Cancer Research ·William M. Lin,Alissa C. Baker,Rameen Beroukhim,Wendy Winckler,Whei Feng,(unknown),Elisabeth Laine,Heidi Greulich,Hsiuyi Tseng,Casey Gates,F. Stephen Hodi,Glenn Dranoff,William R. Sellers,Roman K. Thomas,Matthew Meyerson,Todd R. Golub,Reinhard Dummer,Meenhard Herlyn,Gad Getz,Levi A. Garraway	215
19	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models 2007 ·Cancer Research ·Hongbin Ji,Zhenxiong Wang,Samanthi A. Perera,Danan Li,Mei‐Chih Liang,Sara Zaghlul,Kate McNamara,Liang Chen,Mitchell Albert,Yanping Sun,Ruqayyah Al-Hashem,Lucian R. Chirieac,Robert F. Padera,Roderick T. Bronson,Roman K. Thomas,Levi A. Garraway,Pasi A. Jänne,Bruce E. Johnson,Lynda Chin,Kwok‐Kin Wong	137
20	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis 2005 ·Cancer Research ·Xiaojun Zhao,Barbara A. Weir,Thomas LaFramboise,Ming Gang Lin,Rameen Beroukhim,Levi A. Garraway,Javad Beheshti,Jeffrey C. Lee,Katsuhiko Naoki,William G. Richards,David J. Sugarbaker,Fei Chen,Mark A. Rubin,Pasi A. Jänne,Luc Girard,John D. Minna,David C. Christiani,Cheng Li,William R. Sellers,Matthew Meyerson	242

About Levi A. Garraway

Levi A. Garraway is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 173 papers that have together received 22.5k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (68 papers), Melanoma and MAPK Pathways (40 papers) and Genetic factors in colorectal cancer (15 papers). The work is most often cited by research in Cancer Research (5.6k citations), Oncology (7.0k citations) and Molecular Biology (14.9k citations). Levi A. Garraway has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Eric S. Lander, Matthew Meyerson, Lynda Chin, Gad Getz, William R. Sellers, Todd R. Golub, David E. Fisher, Laura E. MacConaill, Gregory V. Kryukov and Stacey Gabriel. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact